Circulating Tumor Cells and Colorectal Cancer

The significance of circulating tumor cells (CTCs) has been discussed for more than a century. The advent of modern technology has allowed for more reliable detection of CTCs, and recent studies have provided compelling evidence that CTCs predict clinical response in metastatic colorectal cancer (mCRC). Combination of CTC analysis with independent prognostic factors has demonstrated powerful synergy in some studies. The ability of CTCs to predict metastasis and therapy-specific response has high potential clinical utility, with early studies showing promising results in colorectal cancer (CRC). Reliable CTC detection has also allowed for examination of tumor cell dissemination during surgery, and there appears to be a heavy dependence on the approach chosen. This review discusses the evidence for CTC significance, with particular focus on detection methods, novel markers, and clinical outcomes in CRC. Numerous opportunities exist for preclinical, clinical, and translational studies to explore molecular determinants within CTCs, as well as the value of CTCs in directing targeted therapeutics.

[1]  J. Nemunaitis,et al.  Circulating Tumor Cells in Patients Undergoing Surgery for Hepatic Metastases from Colorectal Cancer , 2010, Proceedings.

[2]  M. Koch,et al.  Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies , 2010, BMC biotechnology.

[3]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Li-hua Hu,et al.  Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. , 2008, Japanese journal of clinical oncology.

[5]  Jaw-Yuan Wang,et al.  Enhancing Detection of Circulating Tumor Cells with Activating KRAS Oncogene in Patients with Colorectal Cancer by Weighted Chemiluminescent Membrane Array Method , 2010, Annals of Surgical Oncology.

[6]  A. Darzi,et al.  Does the Presence of Circulating Tumor Cells in the Venous Drainage of Curative Colorectal Cancer Resections Determine Prognosis? A Meta-Analysis , 2008, Annals of Surgical Oncology.

[7]  I. Nagtegaal,et al.  Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[9]  Jaw-Yuan Wang,et al.  Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.

[10]  C. Punt,et al.  Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  O. Jonasson,et al.  Clinical significance of cancer cells in the circulating blood: two- to five-year survival. , 1961 .

[12]  C.-H. Wu,et al.  Detection of circulating cancer cells with K-ras oncogene using membrane array. , 2005, Cancer letters.

[13]  A. Abrantes,et al.  Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  Bingham Ja Letter: Lower oesophageal sphincter. , 1974 .

[15]  S. Yie,et al.  Detection of Survivin-Expressing Circulating Cancer Cells (CCCs) in Peripheral Blood of Patients with Gastric and Colorectal Cancer Reveals High Risks of Relapse , 2008, Annals of Surgical Oncology.

[16]  M. Sanz-Casla,et al.  Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. von Knebel Doeberitz,et al.  Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients. , 2008, International journal of oncology.

[18]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[19]  T. Yau,et al.  A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. , 2010, Cell stem cell.

[20]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[21]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[22]  A. Zaniboni,et al.  Molecular signature detection of circulating tumor cells using a panel of selected genes. , 2008, Cancer letters.

[23]  Jaw-Yuan Wang,et al.  Persistent Presence of Postoperative Circulating Tumor Cells is a Poor Prognostic Factor for Patients with Stage I–III Colorectal Cancer after Curative Resection , 2008, Annals of Surgical Oncology.

[24]  R. Zeillinger,et al.  Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. , 2010, Cancer letters.

[25]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[26]  Engell Hc [Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation]. , 1955 .

[27]  H. Engell Cancer Cells in the Blood: A Five to Nine Year Follow up Study , 1959, Annals of surgery.

[28]  B. Ma,et al.  Isolated Tumor Cells and Circulating CK20 mRNA in pN0 Colorectal Cancer Patients , 2008, International journal of surgical pathology.

[29]  A. Carrato,et al.  Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study , 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[30]  P. B. Lai,et al.  Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients , 2009, Clinical Cancer Research.

[31]  Glenn Heller,et al.  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[32]  G. T. Budd,et al.  Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.

[33]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[34]  David Elashoff,et al.  Prognostic Relevance of Occult Nodal Micrometastases and Circulating Tumor Cells in Colorectal Cancer in a Prospective Multicenter Trial , 2008, Clinical Cancer Research.

[35]  B. Negin,et al.  Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges , 2010, Current treatment options in oncology.

[36]  C. Tinelli,et al.  Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  M. Koch,et al.  Influence of two different resection techniques (conventional liver resection versus anterior approach) of liver metastases from colorectal cancer on hematogenous tumor cell dissemination – prospective randomized multicenter trial , 2008, BMC surgery.